Mosaic ImmunoEngineering Inc. has agreed to acquire the rights to Oncotelic Therapeutics Inc.’s clinical-stage necroptosis cancer therapies.
 
Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death receptor” activation which can result in a robust anti-cancer immune response. In addition to the clinical stage assets, Mosaic will have access to Oncotelic’s proprietary Artificial Intelligence (AI) technologies for identifying immunotherapy combinations.
 
The Mosaic team, which has broad experience in bringing oncology and orphan drug products to market, will be responsible for advancing the development of the technologies. Both companies will work closely together to ensure a smooth transfer of the technologies from Oncotelic to Mosaic. Oncotelic will provide short-term financial support for the program while the teams work together to achieve both short-term and long-term financing goals.
 
“We are very pleased to have this opportunity to bring these clinical stage assets that have promise for the treatment of multiple types of cancer into Mosaic. We anticipate that the initial application of the technology will be in areas with high unmet medical need such as uveal melanoma and retinoblastoma. We look forward to working with the Oncotelic team to advance the program,” said Steven King, President and CEO of Mosaic.